NGM Bio to Present at Two Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NGM Biopharmaceuticals (NGM), a biotechnology company, has announced that CEO David J. Woodhouse, Ph.D., will present a business update at two upcoming investor conferences. The presentations will take place on August 10, 2020, at the BTIG Biotechnology Conference at 11:00 am ET, and on August 13, 2020, at the Canaccord Genuity 40th Annual Growth Conference at 9:00 am ET. A live webcast of these presentations will be available on NGM's website, with a replay accessible for 30 days post-event.
Details
News Market Reaction – NGM
The recorded move for NGM in the trading session of this news was -0.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.
Monday, August 10, 2020
Event: BTIG Biotechnology Conference 2020
Time: 11:00 am ET
Thursday, August 13, 2020
Event: Canaccord Genuity 40th Annual Growth Conference
Time: 9:00 am ET
A live webcast of these presentations will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM’s site for 30 days following the event.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver disease, retinal disease, cancer and metabolic disease. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.
| Investor Contacts: Sylvia Wheeler and Alexandra Santos swheeler@wheelhouselsa.com asantos@wheelhouselsa.com ir@ngmbio.com | Media Contact: Liz Melone media@ngmbio.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.